Nctid:
NCT00001507
Payload:
{"FullStudy"=>{"Rank"=>473872, "Study"=>{"DerivedSection"=>{"MiscInfoModule"=>{"VersionHolder"=>"December 06, 2023"}, "ConditionBrowseModule"=>{"ConditionMeshList"=>{"ConditionMesh"=>[{"ConditionMeshId"=>"D000009369", "ConditionMeshTerm"=>"Neoplasms"}, {"ConditionMeshId"=>"D000009362", "ConditionMeshTerm"=>"Neoplasm Metastasis"}, {"ConditionMeshId"=>"D000001943", "ConditionMeshTerm"=>"Breast Neoplasms"}, {"ConditionMeshId"=>"D000058922", "ConditionMeshTerm"=>"Inflammatory Breast Neoplasms"}]}, "ConditionAncestorList"=>{"ConditionAncestor"=>[{"ConditionAncestorId"=>"D000009385", "ConditionAncestorTerm"=>"Neoplastic Processes"}, {"ConditionAncestorId"=>"D000010335", "ConditionAncestorTerm"=>"Pathologic Processes"}, {"ConditionAncestorId"=>"D000009371", "ConditionAncestorTerm"=>"Neoplasms by Site"}, {"ConditionAncestorId"=>"D000001941", "ConditionAncestorTerm"=>"Breast Diseases"}, {"ConditionAncestorId"=>"D000012871", "ConditionAncestorTerm"=>"Skin Diseases"}]}, "ConditionBrowseLeafList"=>{"ConditionBrowseLeaf"=>[{"ConditionBrowseLeafId"=>"M11997", "ConditionBrowseLeafName"=>"Neoplasm Metastasis", "ConditionBrowseLeafAsFound"=>"Neoplasm Metastasis", "ConditionBrowseLeafRelevance"=>"high"}, {"ConditionBrowseLeafId"=>"M4910", "ConditionBrowseLeafName"=>"Breast Neoplasms", "ConditionBrowseLeafAsFound"=>"Breast Neoplasms", "ConditionBrowseLeafRelevance"=>"high"}, {"ConditionBrowseLeafId"=>"M28985", "ConditionBrowseLeafName"=>"Inflammatory Breast Neoplasms", "ConditionBrowseLeafAsFound"=>"Inflammatory Breast Cancer", "ConditionBrowseLeafRelevance"=>"high"}, {"ConditionBrowseLeafId"=>"M12020", "ConditionBrowseLeafName"=>"Neoplastic Processes", "ConditionBrowseLeafRelevance"=>"low"}, {"ConditionBrowseLeafId"=>"M4908", "ConditionBrowseLeafName"=>"Breast Diseases", "ConditionBrowseLeafRelevance"=>"low"}, {"ConditionBrowseLeafId"=>"M15364", "ConditionBrowseLeafName"=>"Skin Diseases", "ConditionBrowseLeafRelevance"=>"low"}, {"ConditionBrowseLeafId"=>"T3067", "ConditionBrowseLeafName"=>"Inflammatory Breast Cancer", "ConditionBrowseLeafAsFound"=>"Inflammatory Breast Cancer", "ConditionBrowseLeafRelevance"=>"high"}]}, "ConditionBrowseBranchList"=>{"ConditionBrowseBranch"=>[{"ConditionBrowseBranchName"=>"Neoplasms", "ConditionBrowseBranchAbbrev"=>"BC04"}, {"ConditionBrowseBranchName"=>"Symptoms and General Pathology", "ConditionBrowseBranchAbbrev"=>"BC23"}, {"ConditionBrowseBranchName"=>"All Conditions", "ConditionBrowseBranchAbbrev"=>"All"}, {"ConditionBrowseBranchName"=>"Skin and Connective Tissue Diseases", "ConditionBrowseBranchAbbrev"=>"BC17"}, {"ConditionBrowseBranchName"=>"Rare Diseases", "ConditionBrowseBranchAbbrev"=>"Rare"}]}}, "InterventionBrowseModule"=>{"InterventionMeshList"=>{"InterventionMesh"=>[{"InterventionMeshId"=>"D000074322", "InterventionMeshTerm"=>"Antineoplastic Agents, Immunological"}, {"InterventionMeshId"=>"D000000906", "InterventionMeshTerm"=>"Antibodies"}, {"InterventionMeshId"=>"D000007136", "InterventionMeshTerm"=>"Immunoglobulins"}, {"InterventionMeshId"=>"D000000911", "InterventionMeshTerm"=>"Antibodies, Monoclonal"}]}, "InterventionAncestorList"=>{"InterventionAncestor"=>[{"InterventionAncestorId"=>"D000007155", "InterventionAncestorTerm"=>"Immunologic Factors"}, {"InterventionAncestorId"=>"D000045505", "InterventionAncestorTerm"=>"Physiological Effects of Drugs"}, {"InterventionAncestorId"=>"D000000970", "InterventionAncestorTerm"=>"Antineoplastic Agents"}]}, "InterventionBrowseLeafList"=>{"InterventionBrowseLeaf"=>[{"InterventionBrowseLeafId"=>"M9874", "InterventionBrowseLeafName"=>"Immunoglobulins", "InterventionBrowseLeafAsFound"=>"Use", "InterventionBrowseLeafRelevance"=>"high"}, {"InterventionBrowseLeafId"=>"M3915", "InterventionBrowseLeafName"=>"Antibodies", "InterventionBrowseLeafAsFound"=>"Use", "InterventionBrowseLeafRelevance"=>"high"}, {"InterventionBrowseLeafId"=>"M11231", "InterventionBrowseLeafName"=>"Melphalan", "InterventionBrowseLeafRelevance"=>"low"}, {"InterventionBrowseLeafId"=>"M7881", "InterventionBrowseLeafName"=>"Etoposide", "InterventionBrowseLeafRelevance"=>"low"}, {"InterventionBrowseLeafId"=>"M341584", "InterventionBrowseLeafName"=>"Etoposide phosphate", "InterventionBrowseLeafRelevance"=>"low"}, {"InterventionBrowseLeafId"=>"M6417", "InterventionBrowseLeafName"=>"Cyclophosphamide", "InterventionBrowseLeafRelevance"=>"low"}, {"InterventionBrowseLeafId"=>"M3920", "InterventionBrowseLeafName"=>"Antibodies, Monoclonal", "InterventionBrowseLeafAsFound"=>"Assessment", "InterventionBrowseLeafRelevance"=>"high"}, {"InterventionBrowseLeafId"=>"M19227", "InterventionBrowseLeafName"=>"Paclitaxel", "InterventionBrowseLeafRelevance"=>"low"}, {"InterventionBrowseLeafId"=>"M231", "InterventionBrowseLeafName"=>"Albumin-Bound Paclitaxel", "InterventionBrowseLeafRelevance"=>"low"}, {"InterventionBrowseLeafId"=>"M1346", "InterventionBrowseLeafName"=>"Antineoplastic Agents, Immunological", "InterventionBrowseLeafAsFound"=>"Assessment", "InterventionBrowseLeafRelevance"=>"high"}, {"InterventionBrowseLeafId"=>"M18807", "InterventionBrowseLeafName"=>"Immunoglobulins, Intravenous", "InterventionBrowseLeafRelevance"=>"low"}, {"InterventionBrowseLeafId"=>"M9891", "InterventionBrowseLeafName"=>"Immunologic Factors", "InterventionBrowseLeafRelevance"=>"low"}]}, "InterventionBrowseBranchList"=>{"InterventionBrowseBranch"=>[{"InterventionBrowseBranchName"=>"All Drugs and Chemicals", "InterventionBrowseBranchAbbrev"=>"All"}, {"InterventionBrowseBranchName"=>"Antineoplastic Agents", "InterventionBrowseBranchAbbrev"=>"ANeo"}, {"InterventionBrowseBranchName"=>"Antirheumatic Agents", "InterventionBrowseBranchAbbrev"=>"ARhu"}]}}}, "ProtocolSection"=>{"DesignModule"=>{"PhaseList"=>{"Phase"=>["Phase 1"]}, "StudyType"=>"Interventional", "DesignInfo"=>{"DesignPrimaryPurpose"=>"Treatment"}, "EnrollmentInfo"=>{"EnrollmentType"=>"Actual", "EnrollmentCount"=>"107"}}, "StatusModule"=>{"OverallStatus"=>"Completed", "StartDateStruct"=>{"StartDate"=>"July 12, 1996"}, "ExpandedAccessInfo"=>{"HasExpandedAccess"=>"No"}, "StatusVerifiedDate"=>"June 20, 2014", "CompletionDateStruct"=>{"CompletionDate"=>"June 20, 2014", "CompletionDateType"=>"Actual"}, "LastUpdateSubmitDate"=>"December 20, 2018", "StudyFirstSubmitDate"=>"November 3, 1999", "StudyFirstSubmitQCDate"=>"November 3, 1999", "LastUpdatePostDateStruct"=>{"LastUpdatePostDate"=>"December 21, 2018", "LastUpdatePostDateType"=>"Actual"}, "StudyFirstPostDateStruct"=>{"StudyFirstPostDate"=>"November 4, 1999", "StudyFirstPostDateType"=>"Estimate"}, "PrimaryCompletionDateStruct"=>{"PrimaryCompletionDate"=>"June 30, 1998", "PrimaryCompletionDateType"=>"Actual"}}, "OversightModule"=>{}, "ConditionsModule"=>{"KeywordList"=>{"Keyword"=>["T-cells", "CD34+ Selection", "T-Cell Depletion", "Apheresis", "Mobilization"]}, "ConditionList"=>{"Condition"=>["Breast Neoplasm", "Neoplasm Metastasis"]}}, "ReferencesModule"=>{"ReferenceList"=>{"Reference"=>[{"ReferencePMID"=>"8011690", "ReferenceType"=>"background", "ReferenceCitation"=>"Shpall EJ, Jones RB, Bearman S. High-dose therapy with autologous bone marrow transplantation for the treatment of solid tumors. Curr Opin Oncol. 1994 Mar;6(2):135-8. doi: 10.1097/00001622-199403000-00004."}, {"ReferencePMID"=>"8501500", "ReferenceType"=>"background", "ReferenceCitation"=>"Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC Jr, Jones R, Shpall E, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993 Jun;11(6):1132-43. doi: 10.1200/JCO.1993.11.6.1132."}, {"ReferencePMID"=>"7919339", "ReferenceType"=>"background", "ReferenceCitation"=>"Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME, Wexler LH, Adde MA, McClure LL, Gress RE. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 1994 Oct 1;84(7):2221-8."}]}}, "DescriptionModule"=>{"BriefSummary"=>"This study will evaluate the effectiveness of combination chemotherapy with paclitaxel (Taxol) and cyclophosphamide (Cytoxan), followed by high-dose melphalan and etoposide for treating inflammatory breast cancer. Patients also receive infusions of their own previously collected progenitor cells (primitive cells that can make new cells to replace ones destroyed by chemotherapy).\n\nPatients 18 years of age or older with stage IIIB inflammatory breast cancer that has not metastasized (spread beyond the breast) may be eligible for this study. Candidates are screened with a medical history and physical examination, blood and urine tests, and chest x-ray. They have computed tomography (CT) of the head, chest, abdomen and pelvis as well as a bone scan to determine the extent of disease, and a nuclear medicine scan called MUGA to examine the heart's pumping ability. They may receive a rehabilitation medicine evaluation.\n\nParticipants undergo the following tests and procedures:\n\nCentral venous line placement: Patients have a central venous line (plastic tube) placed into a major vein in the chest before beginning treatment. The line remains in the body throughout treatment and is used to give chemotherapy and other medications and to withdraw blood samples. The line is usually placed under local anesthesia in the radiology department or the operating room.\nChemotherapy: Patients receive two or more cycles of paclitaxel and cyclophosphamide. Paclitaxel is given intravenously (I.V., through a vein) for 72 hours using a portable pump. Cyclophosphamide is given daily for 3 days I.V. over 1 hour. The cycles may be 28 days apart. A drug called Mesna is given with this treatment to protect the bladder from irritation from cyclophosphamide. Patients who have not previously been treated with doxorubicin (Adriamycin) may receive a maximum of four cycles of doxorubicin and cyclophosphamide by vein on a single day during each cycle, with cycles 21 days apart. When all the paclitaxel/cyclophosphamide cycles are completed, patients receive melphalan and etoposide, both drugs I.V. over 1 to 8 hours for three consecutive days.\nG-CSF treatment: After each paclitaxel/cyclophosphamide cycle and after the melphalan/etoposide treatment, patients are given a drug called G-CSF. G-CSF, injected under the skin, stimulates production of infection-fighting white blood cells.\nApheresis: This is a procedure to collect progenitor cells for later reinfusion. For this procedure, blood is collected through a catheter (plastic tube) placed in an arm vein. The blood is circulated through a cell-separating machine, where the white cells, including the progenitor cells, are extracted, and the red cells are returned to the patient through another catheter in the other arm. Apheresis is done after each of two cycles of paclitaxel/cyclophosphamide.\nProgenitor cell transplant: Progenitor cells are reinfused after melphalan/etoposide treatment.\nGlucose infusion: A salt solution with chemically modified glucose is infused I.V. over a period of from 12 to 48 hours, with subsequent donation of blood cells for blood and immune system studies. Patients have a maximum of two glucose infusions, separated by at least 3 months.\nTumor biopsy: Some patients have a biopsy of their tumor (removal of a small piece of tumor tissue for microscopic study) before starting chemotherapy.\nBlood tests: Blood is drawn frequently to monitor safety and treatment response, and for research purposes.\nDental consultation: Some patients may have a dental consultation before the progenitor cell transplant.", "DetailedDescription"=>"BACKGROUND:\n\nEfforts to cure high-risk breast cancer have increasingly focused on the application of dose intensive chemotherapy. To date, the use of dose intensive and high-dose chemotherapy has not significantly changed the survival for the majority of high risk and metastatic patients. The optimal schedule and combination of agents to improve the results of high-dose chemotherapy is not known. This study will pilot a combination of chemotherapy agents for the treatment of Inflammatory Breast Cancer.\n\nOBJECTIVES:\n\nTo define, in a statistically relevant manner, the clinical efficacy of this chemotherapy regimen combination in the treatment of Inflammatory Breast Cancer (stage IIIB inflammatory).\n\nTo examine the effects of this high-dose chemotherapy on T-cells (T-cell number, phenotype, cytokine profiles) and study the process of post-chemotherapy T-cell regeneration.\n\nELIGIBILITY:\n\nNewly diagnosed patient with non metastatic Inflammatory Breast Cancer (stage III B).\n\nThe patients treated in this study will also be eligible for entrance into other protocols of the experimental Transplantation & Immunology Branch that are examining strategies of manipulating T-cell regeneration in adults after intensive chemotherapy.\n\nDESIGN:\n\nPatients will receive multiple cycles of a dose intensive combination of Paclitaxel and Cyclophosphamide both for the mobilization of peripheral blood progenitor cells and with therapeutic intent. A second induction regimen will consist of four cycles of the combination of Doxorubicin / cyclophosphamide. Patients will subsequently receive high-dose Melphalan and Etoposide followed by the infusion of peripheral blood progenitor cells and granulocytes colony-stimulating-factor (G-CSF)."}, "EligibilityModule"=>{"Gender"=>"All", "MinimumAge"=>"18 years", "StdAgeList"=>{"StdAge"=>["Adult", "Older Adult"]}, "HealthyVolunteers"=>"No", "EligibilityCriteria"=>"ELIGIBILITY CRITERIA:\n\nINCLUSION CRITERIA:\n\nAge greater or equal to 18 years.\n\nAll patients must have a histologically confirmed diagnosis of Inflammatory Breast Carcinoma stage III B. Patients with no clinical inflammatory signs but with tumor invasion of dermal lymphatic on histology are eligible. Patients with metastatic disease and Inflammatory Breast Carcinoma are not eligible. All pathologic material must be reviewed and confirmed by the Department of Pathology of the treating institution prior to treatment (there will be no central pathology review).\n\nPatients may be untreated or may have received prior induction chemotherapy outside the NCI. If patients received prior induction chemotherapy, they may not have been unresponsive to it. They may have received chemotherapy either before (neo-adjuvant setting) or after local surgery (adjuvant setting).\n\nKarnofsky performance status of greater than 70% (ECOG 0 or 1).\n\nEjection fraction by MUGA or 2-D echocardiogram within institution normal limits.\n\nCreatinine clearance of greater than 60 cc/mm.\n\nAST and ALT less than 3 times the upper limit of normal.\n\nBilirubin less than 1.5 (except in cases of Gilbert's disease).\n\nANC greater than l000/mm(3).\n\nPlatelet count greater than 90,000/mm(3).\n\nDLCO greater than 50%.\n\nNo history of medical or psychiatric disease which would preclude safe treatment in the view of the principal investigator.\n\nNo history of abnormal bleeding tendency or predisposition to repeated infections.\n\nPatients must be able to give informed consent.\n\nEXCLUSION CRITERIA:\n\nPatients with Inflammatory Breast Cancer but with metastatic disease.\n\nAny patient may be excluded from this study at the discretion of the principal investigator if it is deemed that allowing participation would represent an unacceptable medical or psychiatric risk.\n\nAny patient with a need for chronic steroids or anticoagulation will be ineligible.\n\nAny patient testing positive for HIV (AIDS) or hepatitis B or C will be ineligible.\n\nAny female patient known or found to be pregnant will be considered ineligible. Patients of childbearing potential unwilling to practice contraception will be ineligible.\n\nAny patient with an active second malignancy (excluding treated skin cancers or carcinoma in situ) will be ineligible."}, "IdentificationModule"=>{"NCTId"=>"NCT00001507", "BriefTitle"=>"Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer", "Organization"=>{"OrgClass"=>"NIH", "OrgFullName"=>"National Institutes of Health Clinical Center (CC)"}, "OfficialTitle"=>"A Multi-Center Study of Paclitaxel/Cyclophosphamide and High Dose Melphalan/Etoposide With Autologous Progenitor Cell Transplantation for the Treatment of Inflammatory Breast Cancer", "NCTIdAliasList"=>{"NCTIdAlias"=>["NCT00019162"]}, "OrgStudyIdInfo"=>{"OrgStudyId"=>"960104"}, "SecondaryIdInfoList"=>{"SecondaryIdInfo"=>[{"SecondaryId"=>"96-C-0104"}]}}, "ArmsInterventionsModule"=>{"InterventionList"=>{"Intervention"=>[{"InterventionName"=>"Monoclonal Antibody 3A1", "InterventionType"=>"Drug"}, {"InterventionName"=>"Monoclonal Antibody 95-5-49", "InterventionType"=>"Drug"}, {"InterventionName"=>"Monoclonal Antibody 95-6-22", "InterventionType"=>"Drug"}, {"InterventionName"=>"Baxter Isolex 3001 Stem Cell Selection System", "InterventionType"=>"Device"}, {"InterventionName"=>"Ceprate SC", "InterventionType"=>"Device"}]}}, "ContactsLocationsModule"=>{"LocationList"=>{"Location"=>[{"LocationZip"=>"20892", "LocationCity"=>"Bethesda", "LocationState"=>"Maryland", "LocationCountry"=>"United States", "LocationFacility"=>"National Institutes of Health Clinical Center, 9000 Rockville Pike"}]}, "OverallOfficialList"=>{"OverallOfficial"=>[{"OverallOfficialName"=>"Ronald E Gress, M.D.", "OverallOfficialRole"=>"Principal Investigator", "OverallOfficialAffiliation"=>"National Cancer Institute (NCI)"}]}}, "SponsorCollaboratorsModule"=>{"LeadSponsor"=>{"LeadSponsorName"=>"National Cancer Institute (NCI)", "LeadSponsorClass"=>"NIH"}}}}}}
